Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medimaging Integrated SolutionTPE:6796 -1.35%74 Return-on-Tangible-Equity is 19.47% as of Dec. 2025, which is 68% above its 10-year median of 11.56. GuruFocus rates TPE:6796 with a GF Score™ of 74/100 and a GF Value™ of NT$106.49 (Significantly Undervalued). The stock has 9 warning signs investors should review. Among 760 Medical Devices & Instruments companies, Medimaging Integrated Solution ranks worse than 56.84% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Medimaging Integrated Solution's annualized net income for the quarter that ended in Dec. 2025 was NT$135.1 Mil. Medimaging Integrated Solution's average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$693.7 Mil. Therefore, Medimaging Integrated Solution's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 19.47%.
The historical rank and industry rank for Medimaging Integrated Solution's Return-on-Tangible-Equity or its related term are showing as below:
TPE:6796'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0.75 Med: 11.56 Max: 15.8
Current: 1.11
During the past 8 years, Medimaging Integrated Solution's highest Return-on-Tangible-Equity was 15.80%. The lowest was 0.75%. And the median was 11.56%.
TPE:6796's Return-on-Tangible-Equity is ranked worse than 56.84% of 760
companies
in the Medical Devices & Instruments industry
Industry Median: 4.03
vs TPE:6796: 1.11
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Medimaging Integrated Solution Return-on-Tangible-Equity Related Terms
Medimaging Integrated Solution Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6796 vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Medimaging Integrated Solution's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medimaging Integrated Solution Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medimaging Integrated Solution's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Medimaging Integrated Solution's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 19.47% mean?
Medimaging Integrated Solution (TPE:6796) has a Return-on-Tangible-Equity of 19.47% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medimaging Integrated Solution and its competitors. This is 68% above median its historical median of 11.56. Over the past decade, Medimaging Integrated Solution's Return-on-Tangible-Equity has ranged from 0.75 to 15.80. According to the industry distribution chart, Medimaging Integrated Solution ranks #432 out of 760 companies in the Medical Devices & Instruments industry, placing it in the top 56.8%.
Is Medimaging Integrated Solution's Return-on-Tangible-Equity too high?
Medimaging Integrated Solution's current Return-on-Tangible-Equity of 19.47% is 68% above median its 10-year median of 11.56. Over the past 10 years, this metric has ranged from a low of 0.75 to a high of 15.80. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.03. Medimaging Integrated Solution's value of 19.47% is 383.1% above this industry median. Based on the distribution chart, Medimaging Integrated Solution ranks #432 out of 760 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Medimaging Integrated Solution has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medimaging Integrated Solution's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medimaging Integrated Solution ranks #432 out of 760 companies for Return-on-Tangible-Equity. This places Medimaging Integrated Solution in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.03. Medimaging Integrated Solution's value of 19.47% is 383.1% above this benchmark. Historically, Medimaging Integrated Solution's own Return-on-Tangible-Equity has ranged from 0.75 to 15.80 over the past decade. While the company's 10-year median is 11.56 vs. the industry median of 4.03, Medimaging Integrated Solution has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.03, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medimaging Integrated Solution's current Return-on-Tangible-Equity of 19.47% is 383.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medimaging Integrated Solution and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medimaging Integrated Solution's current Return-on-Tangible-Equity is 19.47%, which is 68% above median its own 10-year median of 11.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medimaging Integrated Solution stock overvalued right now?
Based on GuruFocus' analysis, Medimaging Integrated Solution (TPE:6796) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$106.49, compared to a current price of NT$58.40 — trading 45.2% below its estimated fair value. The current Return-on-Tangible-Equity is 19.47%, which is 68% above median its 10-year median of 11.56 and 383.1% above the Medical Devices & Instruments industry median of 4.03. Medimaging Integrated Solution's overall GF Score™ is 74/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Medimaging Integrated Solution (TPE:6796), the current Return-on-Tangible-Equity is 19.47% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medimaging Integrated Solution (TPE:6796) Overvalued in 2026?
Based on GuruFocus' analysis, Medimaging Integrated Solution stock appears to be undervalued.
The current stock price of NT$58.40 is trading 45.2% below its estimated GF Value™ of NT$106.49.
GuruFocus considers Medimaging Integrated Solution to be Significantly Undervalued.
Key valuation signals for TPE:6796:
Return-on-Tangible-Equity: 19.47% (68% above median its 10-year median of 11.56)
GF Value™: NT$106.49 vs. price of NT$58.40 (45.2% below fair value)
Industry Position: 383.1% above the Medical Devices & Instruments median (#432 of 760)
No single metric tells the full story. See the TPE:6796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medimaging Integrated Solution Business Description
Medimaging Integrated Solution Inc and its subsidiaries are engaged in the design, manufacturing, and sales of digital medical imaging diagnostic equipment and related products and services. The company is a trusted partner of hospitals, medical schools, and health organizations, providing practitioners with digital and portable diagnostic solutions. The company designs and manufactures digital hand-held diagnostic scopes. Its products include Horus Scope, Smart Solutions, Endoscopy, and Micro Camera Modules.
74GF Score
Get the complete analysis for TPE:6796
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6796 has been successfully added to your 
